ReviewFrontiers in endocrinology2026
Sex hormones and functional gastrointestinal disorders in menopausal women.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Functional gastrointestinal diseases (FGIDs)/disorders of gut-brain interaction (DGBI) that manifest during menopause are characterized by chronic recurrent gastrointestinal (GI) symptoms associated with fluctuations in sex hormones. Current research indicates that the regulatory influence of sex hormones on GI function is multifaceted, involving a complex endocrine regulatory network across multiple organs and systems. Various types of sex hormones exert both direct and indirect effects on GI function through their specific receptors located within the GI tract, the central nervous system, pancreatic islets, and thyroid tissue. This interplay contributes to the pathological and physiological mechanisms underlying the onset of menopausal FGIDs/DGBI. Simultaneously, these interactions create a complex pathological feedback loop with climacteric syndrome, depression/anxiety, and sleep disorders. In this study, we present a comprehensive narrative review detailing the molecular mechanisms by which sex hormones regulate GI function-both directly and indirectly-as well as examining the impact of clinical hormone replacement therapy on GI functionality. Our objective is to elucidate potential pathogenesis pathways for FGIDs/DGBI in menopausal women linked to changes in sex hormone levels, further clarify the relationship between hormonal fluctuations and GI function, and propose new therapeutic strategies for managing FGIDs/DGBI. Additionally, alterations in gut microbiota may play a significant role in mediating interactions between sex hormones and the gut-brain axis. This exploration also offers fresh insights and avenues for future clinical research into the relationship between sex hormones and FGIDs/DGBI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.